CYP2D6*10 pharmacogenetic-guided SERM could be a cost-effective strategy in Chinese patients with hormone receptor-positive breast cancer
| العنوان: | CYP2D6*10 pharmacogenetic-guided SERM could be a cost-effective strategy in Chinese patients with hormone receptor-positive breast cancer |
|---|---|
| المؤلفون: | Jie Zhuang, Hong Sun, Bin Zheng, Jiaqin Cai, Xiaoxia Wei, Guifeng Zhang, Ying Lin, Yuxia Sui |
| المصدر: | Pharmacogenomics. 21:43-53 |
| بيانات النشر: | Future Medicine Ltd, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, Cost effectiveness, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Internal medicine, Genetics, Medicine, 030212 general & internal medicine, Toremifene, skin and connective tissue diseases, health care economics and organizations, Genetic testing, Pharmacology, medicine.diagnostic_test, business.industry, medicine.disease, Selective estrogen receptor modulator, Hormone receptor, 030220 oncology & carcinogenesis, Molecular Medicine, business, Tamoxifen, Pharmacogenetics, medicine.drug |
| الوصف: | Aim: To assess the cost–effectiveness of CYP2D6*10 genetic testing for the management of Chinese women with hormone receptor-positive (HR+) breast cancer treated with selective estrogen receptor modulator. Methods: A Markov model was developed to evaluate a total expected cost and an incremental cost-effectiveness ratio (ICER). Robustness of the model was addressed in one-way analyses and probabilistic sensitivity analysis. Results: The cost of strategies of tamoxifen, toremifene without genotyping and the strategy base on CYP2D6*10 genotype were $63,879.19, $90,156.60 and $95,021.41, and the quality-adjusted life years gained are 8.1588, 12.89687 and 13.85911, respectively. The incremental cost-effectiveness ratio of the CYP2D6*10 testing versus toremifene were 5,055.74221/quality-adjusted life year, respectively. Conclusion: CYP2D6*10 pharmacogenetic-guided selective estrogen receptor modulator can be a cost-effective strategy in the Chinese patients with hormone receptor-positive breast cancer. |
| تدمد: | 1744-8042 1462-2416 |
| DOI: | 10.2217/pgs-2019-0073 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::174ebd51e4307302704c4a7b48b11859 https://doi.org/10.2217/pgs-2019-0073 |
| رقم الانضمام: | edsair.doi...........174ebd51e4307302704c4a7b48b11859 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17448042 14622416 |
|---|---|
| DOI: | 10.2217/pgs-2019-0073 |